Kalaris Therapeutics, Inc. (KLRS)
Nasdaq: KLRS · Biological Products, (No Diagnostic Substances) · Berkeley Heights, NJ · filing with the SEC since 2018
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Report filed | Mar 17, 2026 | Mar 7, 2025 | Mar 15, 2024 | Feb 15, 2023 | Feb 10, 2022 | Feb 12, 2021 | · |
| Revenue | · | · | · | · | · | · | 165 |
| Research and development | 30,753 | 45,042r | 133,070 | 118,870 | 120,735 | 49,663 | 16,248 |
| General and administrative | 15,399 | 6,690r | 48,261 | 52,332 | 49,083 | 21,646 | 10,618 |
| Total operating expenses | 46,152 | 51,732r | 199,901 | 171,202 | 169,818 | 71,309 | 26,866 |
| Operating income | -46,152 | -51,732r | -199,901 | -171,202 | -169,818 | -71,309 | -26,701 |
| Interest expense | 1,443 | 2,701 | · | · | · | · | · |
| Interest and investment income | · | 5,486 | 5,734 | 1,876 | 1,315 | 1,330 | 2,065 |
| Other income (expense), net | 2,749 | 188r | 3,623 | 351 | -2,452 | 195 | 797 |
| Total non-operating income (expense) | 2,714 | -17,435 | · | · | · | · | · |
| Income before income taxes | -43,438 | -69,167r | -190,544 | -168,975 | -170,955 | -69,784 | -23,839 |
| Income tax expense | 0 | 0 | -126 | -265 | 1,007 | · | · |
| Net income including non-controlling interests | -43,438 | -69,167r | -190,418 | -168,710 | -171,962 | -69,784 | -23,839 |
| Net income | -43,438 | -69,167r | -190,418 | -168,710 | -171,962 | -69,784 | -23,839 |
| Earnings per share, basic | -2.85 | -51.77r | -42.09r | -50.60b | -63.02b | · | · |
| Earnings per share, diluted | -2.85 | -51.77r | -42.09r | -50.60b | -63.02b | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -63.02b | -59.57b | -426.42b |
| Weighted average shares, basic | 15,267,817 | 1,335,925r | 4,524,226r | 3,332,820b | 2,729,658b | · | · |
| Weighted average shares, diluted | 15,267,817 | 1,335,925r | 4,524,226r | 3,332,820b | 2,729,658b | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 2,729,658b | 1,169,452b | 55,910b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-23 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted